The shares of InspireMD, Inc. have increased by more than 24.17% this year alone. The shares recently went up by 16.01% or $0.77 and now trades at $5.58. The shares of Cytori Therapeutics, Inc. (NASDAQ:CYTX), has jumped by 18.97% year to date as of 02/14/2018. The shares currently trade at $0.36 and have been able to report a change of -0.88% over the past one week.
The stock of InspireMD, Inc. and Cytori Therapeutics, Inc. were two of the most active stocks on Wednesday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.
Profitability and Returns
Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. These figures suggest that NSPR ventures generate a higher ROI than that of CYTX.
The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, NSPR’s free cash flow per share is a negative -0.07, while that of CYTX is also a negative -0.09.
Liquidity and Financial Risk
The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for NSPR is 2.30 and that of CYTX is 0.50. This implies that it is easier for NSPR to cover its immediate obligations over the next 12 months than CYTX. The debt ratio of NSPR is 0.00 compared to 1.73 for CYTX. CYTX can be able to settle its long-term debts and thus is a lower financial risk than NSPR.
NSPR currently trades at a P/B of 16.41, and a P/S of 118.65 while CYTX trades at a P/B of 1.56, and a P/S of 1.72. This means that looking at the earnings, book values and sales basis, NSPR is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.
Analyst Price Targets and Opinions
The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of NSPR is currently at a 86% to its one-year price target of 3.00. Looking at its rival pricing, CYTX is at a -82.69% relative to its price target of 2.08. This figure implies that over the next one year, CYTX is a better investment.
When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), NSPR is given a 2.00 while 2.30 placed for CYTX. This means that analysts are more bullish on the outlook for CYTX stocks.
Insider Activity and Investor Sentiment
Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for NSPR is 11.13 while that of CYTX is just 1.46. This means that analysts are more bullish on the forecast for CYTX stock.
The stock of Cytori Therapeutics, Inc. defeats that of InspireMD, Inc. when the two are compared, with CYTX taking 5 out of the total factors that were been considered. CYTX happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, CYTX is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for CYTX is better on when it is viewed on short interest.